{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:25:30Z","timestamp":1785173130658,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s40265-016-0598-8","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T05:57:50Z","timestamp":1464847070000},"page":"1023-1030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Secukinumab: A Review in Ankylosing Spondylitis"],"prefix":"10.1007","volume":"76","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,2]]},"reference":[{"issue":"9570","key":"598_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"issue":"2","key":"598_CR2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2015","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;68(2):282\u201398.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"598_CR3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"598_CR4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/BOR.0b013e3283524b82","volume":"24","author":"U Kiltz","year":"2012","unstructured":"Kiltz U, Heldmann F, Baraliakos X, et al. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol. 2012;24(3):252\u201360.","journal-title":"Curr Opin Rheumatol"},{"key":"598_CR5","doi-asserted-by":"crossref","unstructured":"Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii116\u201323.","DOI":"10.1136\/annrheumdis-2012-202371"},{"issue":"2","key":"598_CR6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","volume":"11","author":"E Toussirot","year":"2012","unstructured":"Toussirot E. The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11(2):159\u201368.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"2","key":"598_CR7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","volume":"30","author":"Y Mei","year":"2011","unstructured":"Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269\u201373.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"598_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","volume":"16","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16(4):323\u201330.","journal-title":"Am J Clin Dermatol"},{"key":"598_CR9","doi-asserted-by":"crossref","unstructured":"Shirley M. Secukinumab: a review in psoriatic arthritis. Drugs. 2016 (In press).","DOI":"10.1007\/s40265-016-0602-3"},{"key":"598_CR10","unstructured":"Novartis. COSENTYX\u00ae (secukinumab) injection, for subcutaneous use: prescribing information. 2016. http:\/\/www.accessdata.fda.gov . Accessed 25 May 2016."},{"key":"598_CR11","unstructured":"Novartis Europharm Limited. Cosentyx: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003729\/human_med_001832.jsp&mid=WC0b01ac058001d124 . Accessed 25 May 2016."},{"issue":"9906","key":"598_CR12","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705\u201313.","journal-title":"Lancet"},{"issue":"2","key":"598_CR13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","volume":"75","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2015;75(2):408\u201312.","journal-title":"Ann Rheum Dis"},{"key":"598_CR14","unstructured":"European Medicines Agency. Assessment report EMA\/CHMP\/665405\/2015: Cosentyx (secukinumab). 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/003729\/WC500199574.pdf . Accessed 25 May 2016."},{"issue":"26","key":"598_CR15","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"598_CR16","first-page":"141","volume":"22","author":"A Kivitz","year":"2016","unstructured":"Kivitz A, Blanco R, Maradiaga M, et al. Secukinumab reduces signs and symptoms of active ankylosing spondylitis: results from a 16-week, randomised, placebo-controlled phase 3 trial [abstract no. 3287319]. J Clin Rheumatol. 2016;22(3):141.","journal-title":"J Clin Rheumatol."},{"key":"598_CR17","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 25 May 2016."},{"issue":"Suppl 10","key":"598_CR18","first-page":"3482","volume":"67","author":"D Baeten","year":"2015","unstructured":"Baeten D, Blanco R, Geusens P, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis in anti-TNF-naive patients and those previously exposed to anti-TNF therapy: 52-week results from two randomized, double-blind, placebo-controlled phase 3 trials [abstract no. 2890]. Arthritis Rheumatol. 2015;67(Suppl 10):3482\u20134.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"598_CR19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/annrheumdis-2015-eular.6726","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Baraliakos X, et al. Secukinumab efficacy in anti-TNF-naive patients and patients previously exposed to anti-TNF therapy: results of a randomized, double-blind, placebo-controlled phase 3 study (MEASURE 2) in active ankylosing spondylitis [abstract no. THU0210]. Ann Rheum Dis. 2015;74(Suppl 2):272.","journal-title":"Ann Rheum Dis"},{"key":"598_CR20","unstructured":"Wei J, Baeten D, Sieper J, et al. Secukinumab improves signs and symptoms of active ankylosing spondylitis in Asian patients: pooled results from two phase 3 trials [abstract no. APL15-0425]. Int J Rheum Dis. 2015;18(Suppl 1):25."},{"issue":"Suppl 10","key":"598_CR21","first-page":"3490","volume":"67","author":"D Baeten","year":"2015","unstructured":"Baeten D, Braun J, Sieper J, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract no. 2896]. Arthritis Rheumatol. 2015;67(Suppl 10):3490\u20132.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"598_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/annrheumdis-2015-eular.6840","volume":"74","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Braun J, Sieper J, et al. Secukinumab reduces sacroiliac joint and spinal inflammation in patients with ankylosing spondylitis: MRI data from a phase 3 randomized, double-blind, placebo-controlled study (MEASURE 1) [abstract no. THU0233]. Ann Rheum Dis. 2015;74(Suppl 2):281.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"598_CR23","first-page":"3939","volume":"67","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Deodhar AA, Braun J, et al. Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab [abstract no. 6L]. Arthritis Rheumatol. 2015;67(Suppl 10):3939\u201341.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"598_CR24","first-page":"1144","volume":"74","author":"A Deodhar","year":"2015","unstructured":"Deodhar A, Sieper J, Emery P, et al. Secukinumab significantly improves physical function, quality of life, and work productivity through 52 weeks in subjects with active ankylosing spondylitis in the phase 3 MEASURE 2 study [abstract no. AB0736]. Ann Rheum Dis. 2015;74(Suppl 2):1144.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"598_CR25","first-page":"S233","volume":"66","author":"AA Deodhar","year":"2014","unstructured":"Deodhar AA, Baeten DL, Braun J, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves physical function and quality of life in subjects with active ankylosing spondylitis: results of a phase 3 randomized, placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing [abstract no. 538]. Arthritis Rheumatol. 2014;66(Suppl 10):S233\u20134.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 10","key":"598_CR26","first-page":"3478","volume":"67","author":"AA Deodhar","year":"2015","unstructured":"Deodhar AA, Baeten D, Sieper J, et al. Safety and tolerability of secukinumab in patients with active ankylosing spondylitis: pooled safety analysis of two phase 3, randomized, controlled trials [abstract no. 2887]. Arthritis Rheumatol. 2015;67(Suppl 10):3478\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"598_CR27","doi-asserted-by":"crossref","unstructured":"Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2010;2(3):256\u201365.","DOI":"10.4161\/mabs.2.3.11641"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0598-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0598-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0598-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:33:04Z","timestamp":1498318384000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0598-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,2]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0598-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,2]]}}}